The abstract is read at the publisher; the summary is JClub's.
In rodents, combining a PDE9 inhibitor with psilocybin attenuates psilocybin-induced head-twitch while preserving an antidepressant-like behavioral response.
- Why it matters: Psilocybin’s antidepressant benefits are constrained by perceptual side effects, so improving tolerability without losing antidepressant-like efficacy is a key gap.
- What they did: The study tested whether boosting cGMP signaling via a phosphodiesterase-9 inhibitor would change a rodent behavioral readout linked to 5-HT2AR activation and antidepressant-like effects.
- The result: The PDE9 inhibitor–psilocybin combination reduced 5-HT2AR-related pathways and enhanced synaptogenesis signaling, implying synaptic proteome restructuring alongside maintained antidepressant-like response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.